Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
VANCOUVER, British Columbia, Aug. 02, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming Canaccord Genuity 37th Annual Growth Conference in New York, NY on Wednesday, August 9th 2017 at 5:00 PM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/canaccord26/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
